Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). Colorectal cancer kills more than 800,000 people a year, was diagnosed in 1.8 million patients in 2018 and is the third most common cancer in men and second in women. Less than 60 % of patients in Europe survive 5 years after detection of this cancer, which in addition is not susceptible to chemotherapy, and as much as 33 % of patients whose phase III tumour has been surgically removed experience recurrence of cancer in aggressive form, metastasised to the liver, lungs and stomach. The aim of the project is to develop the first oral therapy aimed at the main cause of colon cancer, i.e. the signal path of Wnt, using the technology of targeted protein degradation. The molecular goal is a key component of this pathway, whose incorrect activation initiates transcription of important oncogenes, i.e. c-Myc and CyclinD-1, as a consequence promoting the development of cancer, metastasis and resistance to chemotherapy. The project will develop an innovative low-molecule chemical that induces selective degradation of the main regulator of transcription of Wnt pathway proteins. This will be the first treatment in class and the world’s first targeted therapy for patients suffering from colorectal cancer. The use of targeted degradation technology will support the natural control mechanisms of the cell, thereby reducing the likelihood of side effects. The developed degrader will be tested in preclinical and Phase I clinical trials.